BLPH

Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease

Here is What Hedge Funds Think About Bellerophon Therapeutics, Inc. (BLPH)

Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19

Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results